| Literature DB >> 33319626 |
Sanjay Kalra1, Das A K2, Fariduddin Md3, Shaikh K4, Shah P5, Rehim A A6, John M7, Shaikh S8, Orabi A9, Saraswati M R10, Shahjada Selim11, Baruah M P12, K K Gangopadhyay13, Langi Y A14, Nair T15, Dhanwal D16, Thapa S D17, Deshmukh V18, D Dutta19, Khalfan H20, Maskey R21, Das S22, Dasgupta A23, Bajaj A24, Priya G25, Chandrasekaran S26, A Dhingra27, Pandey N28, Al Ani A29, Moosa M30.
Abstract
Type 2 diabetes mellitus (T2DM) is a global epidemic. According to international guidelines, the management protocol of T2DM includes lowering of blood glucose, along with preventing disease-related complications and maintaining optimal quality of life. Further, the guidelines recommend the use of a patient-centric approaches for the management of T2DM; however, Asian population is underrepresented in landmark cardiovascular outcome trials (CVOTs). There are several guidelines available today for the diagnosis and management of T2DM, and hence there is much confusion among practitioners about which guidelines to follow. A group of thirty international clinical experts comprising of endocrinologists, diabetologists and cardiologist from South Asia, Middle East and Africa met at New Delhi, India on February 8 and 9, 2020 and developed an international expert opinion statements via a structured modified Delphi method on the glucodynamic properties of OADs and the glucocratic treatment approach for the management of T2DM. In this modified Delphi consensus report, we document the glucodynamic properties of Modern SUs in terms of glucoconfidence, glucosafety, and gluconomics. According to glucodynamics theory, an ideal antidiabetic drug should be efficacious, safe, and affordable. Modern SUs as a class of OADs that have demonstrated optimal glucodynamics in terms of glucoconfidence, glucosafety, and gluconomics. Hence, modern SUs are most suitable second line drug after metformin for developing countries. Based on the current evidence, we recommend a glucocratic approach for the treatment of T2DM, where an individualized treatment plan with phenotype, lifestyle, environmental, social, and cultural factors should be considered for persons with T2DM in the South Asian, Middle Eastern and African regions.Entities:
Keywords: CAROLINA trial; Delphi consensus; Sulfonylureas; T2DM; cardiovascular safety; glimepiride; glycemic control
Year: 2021 PMID: 33319626 DOI: 10.1080/03007995.2020.1864309
Source DB: PubMed Journal: Curr Med Res Opin ISSN: 0300-7995 Impact factor: 2.580